Review Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Indicator: Together with chemotherapy, for the treatment of adult clients with domestically recurrent unresectable or metastatic triple-unfavorable breast cancer which have not received prior chemotherapy for metastatic disorder and whose tumours Categorical programmed mobile death-ligand 1 (mixed constructive rating ≥ t... https://billw467uwx1.blog-gold.com/profile